Aveo Pharmaceuticals Equity 2024

Aveo Pharmaceuticals Aktienanalyse

What does Aveo Pharmaceuticals do?

Aveo Pharmaceuticals Inc. is a bio-pharmaceutical company focused on the development of new therapies for cancer patients. The company was founded in 2001 in Cambridge, Massachusetts and is listed on the NASDAQ stock exchange under the ticker symbol AVEO. The history of Aveo Pharmaceuticals began with the discovery of a growth factor responsible for the formation of blood vessels in tumors. In collaboration with Harvard Medical School and the Dana-Farber Cancer Institute, the company developed a new drug called Tivozanib, which can block this growth factor. Tivozanib has been tested as a potential treatment for various types of cancer, including kidney cancer, breast cancer, and lung cancer, and is currently in various stages of development. Aveo Pharmaceuticals employs a collaborative business model to involve scientists and researchers in the development of new therapies. The company works together with leading academic institutions and bio-pharmaceutical companies to accelerate and improve the drug development process. Aveo Pharmaceuticals is divided into different divisions that focus on the development of therapies for different types of cancer. These divisions include oncology, which focuses on the development of therapies for solid tumors, as well as hematology, which focuses on the development of therapies for blood cancer. Aveo Pharmaceuticals also has a pipeline of products in various stages of development. These products include both novel drugs and therapies that are already on the market. One of Aveo Pharmaceuticals' most promising products is the drug Tivozanib. Tivozanib is a kinase inhibitor specifically designed for the treatment of kidney cancer. The drug has proven to be effective in clinical trials and could soon be approved by the U.S. Food and Drug Administration (FDA). Tivozanib could improve both the quality of life and the survival rate of kidney cancer patients. Another promising drug from Aveo Pharmaceuticals is Ficlatuzumab, a drug specifically designed for the treatment of solid tumors. Ficlatuzumab targets the hepatocyte growth factor receptor (HGFR), which is overexpressed in various types of cancer such as breast cancer, lung cancer, and pancreatic cancer. The drug is currently in clinical trials and has the potential to become a new treatment option for cancer patients. Over the years, Aveo Pharmaceuticals has received numerous awards and recognitions, including being recognized as one of the "50 Most Innovative Companies in the World" by Technology Review and being included in the "Forbes 200 Best Small Companies in America" ranking. In summary, Aveo Pharmaceuticals is an innovative bio-pharmaceutical company focused on the development of vital therapies for cancer patients. Aveo Pharmaceuticals' collaborative business model has enabled the company to work closely with leading academic institutions and bio-pharmaceutical companies to develop new drugs that could improve the lives of cancer patients. With Tivozanib and Ficlatuzumab, Aveo Pharmaceuticals has two promising drugs in the pipeline that have the potential to change the face of cancer treatment. Aveo Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Aveo Pharmaceuticals's Equity

Aveo Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Aveo Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Aveo Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Aveo Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Aveo Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Aveo Pharmaceuticals stock

What is the equity of Aveo Pharmaceuticals this year?

Aveo Pharmaceuticals has equity of 45.87 M USD this year.

What was the equity of Aveo Pharmaceuticals compared to the previous year?

The equity of Aveo Pharmaceuticals has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of Aveo Pharmaceuticals?

A high equity is advantageous for investors of Aveo Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Aveo Pharmaceuticals?

A low equity can be a risk for investors of Aveo Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Aveo Pharmaceuticals affect the company?

An increase in equity of Aveo Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Aveo Pharmaceuticals affect the company?

A reduction in equity of Aveo Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Aveo Pharmaceuticals?

Some factors that can affect the equity of Aveo Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Aveo Pharmaceuticals so important for investors?

The equity of Aveo Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Aveo Pharmaceuticals take to change the equity?

To change equity, Aveo Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Aveo Pharmaceuticals pay?

Over the past 12 months, Aveo Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aveo Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aveo Pharmaceuticals?

The current dividend yield of Aveo Pharmaceuticals is .

When does Aveo Pharmaceuticals pay dividends?

Aveo Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aveo Pharmaceuticals?

Aveo Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aveo Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aveo Pharmaceuticals located?

Aveo Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aveo Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aveo Pharmaceuticals from 8/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/3/2024.

When did Aveo Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/3/2024.

What was the dividend of Aveo Pharmaceuticals in the year 2023?

In the year 2023, Aveo Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aveo Pharmaceuticals pay out the dividend?

The dividends of Aveo Pharmaceuticals are distributed in USD.